BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?

Sai Prasad DesikanSangeetha VenugopalAlessandra Ferrajoli

Published in: Expert review of hematology (2022)

The choice of BTK inhibitor is guided by the setting (frontline vs relapsed) in conjunction with patient disease characteristics and comorbidities. In this review, we will elucidate our approach to the selection of BTK inhibitor and provide insight into the future of BTK directed therapy.

Keyphrases

tyrosine kinase
chronic lymphocytic leukemia
case report
acute lymphoblastic leukemia
emergency department
current status
hodgkin lymphoma
decision making